Fig. 6

The predictive capacity of the IS scores in assessing the response of cancer patients to immunotherapy. (A) The study demonstrates the use of PD-1 inhibitors in melanoma patients. (B) The study depicts the combined use of PD-1 inhibitors and CTLA-4 inhibitors in melanoma patients. (C). The study displays the use of PD-1 inhibitors in gastric cancer patients. (D) The study demonstrates the use of CTLA-4 inhibitors in melanoma patients. (E) The study represents the application of ACT therapy in melanoma patients. (F–H) Segment patients into groups based on the median IS score for Kaplan–Meier analysis to compare overall survival (OS) and progression-free survival (PFS) between the groups. (F,G) Focus on the use of PD-1 inhibitors alone in the treatment of melanoma. (H) The study shows the use of PD1 inhibitors in a cohort of urothelial carcinoma. (I) Compare the IS score between responders and non-responders to immunotherapy in urothelial carcinoma (P = 0.02). (J–L) Examine the relationship between the IS score and levels of response to immunotherapy across three independent transcriptomic datasets of colon cancer.